Patients treated with OPT-302 from Opthea Limited plus ranibizumab demonstrated better anatomical changes over those treated with ranibizumab alone in a phase 2b study.
The international, multicenter, prospective, sham-controlled, double-masked superiority study included 366 patients with wet age-related macular degeneration who received OPT-302 0.5 mg in combination with Lucentis (ranibizumab, Genentech), OPT-302 2 mg in combination with ranibizumab or sham in combination with ranibizumab.
Patients in the 2 mg combination group saw a decrease in wet AMD total lesion area at 24 weeks of 4.33
Uncategorized